替格瑞洛与氯吡格雷在冠状动脉旁路移植术后的抗血小板效果:单中心随机对照试验
该单中心随机开放标签试验纳入140例冠状动脉旁路移植术患者,1:1随机分为阿司匹林+替格瑞洛组(替格瑞洛90mg每日两次)和阿司匹林+氯吡格雷组(氯吡格雷75mg每日一次)。结果显示替格瑞洛组在首次给药后2小时及研究期间各时间点的血小板聚集抑制率均显著高于氯吡格雷组,且更多患者在24小时内达到最大抑制率,两组出血和主要不良心脏事件无差异。
要点
- 替格瑞洛组2小时血小板聚集抑制率34.2% vs 氯吡格雷组5.3%(P<.001)。
- 替格瑞洛组24小时内达最大抑制率者52.9% vs 氯吡格雷组27.5%(P=.006)。
- 两组出血和主要不良心脏事件无差异。
核心结论
- 在冠状动脉旁路移植术患者中,替格瑞洛起效更快且血小板聚集抑制峰值更高。
研究设计与样本
- 单中心、随机、开放标签研究,纳入140例冠状动脉旁路移植术患者,1:1随机分为阿司匹林+替格瑞洛组或阿司匹林+氯吡格雷组。
主要发现
- 首次给药后2小时血小板聚集抑制率替格瑞洛组为34.2%(四分位距9.1-66.0),氯吡格雷组为5.3%(四分位距-14.3-22.0),P<.001。
- 研究期间各时间点血小板聚集抑制率替格瑞洛组均高于氯吡格雷组(P<.001)。
- 24小时内达到血小板聚集抑制率最大值者替格瑞洛组52.9%,氯吡格雷组27.5%,P=.006。
- 2至24小时平均血小板聚集抑制率最大值替格瑞洛组72.3%±15.4%,氯吡格雷组49.2%±46.8%,P<.001。
- 两组出血或主要不良心脏事件无差异。
关键数值与推荐
- 替格瑞洛组:阿司匹林100mg每日一次+替格瑞洛90mg每日两次;氯吡格雷组:阿司匹林100mg每日一次+氯吡格雷75mg每日一次。
临床怎么用
- 冠状动脉旁路移植术后需快速抗血小板抑制时可优先考虑替格瑞洛方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The study objective was to compare the onset of platelet inhibition (inhibition of platelet aggregation) between ticagrelor 90 mg twice per day and clopidogrel 75 mg once per day in patients receiving coronary artery bypass grafting. METHODS: In a single-center, randomized, open-label study, 140 patients receiving coronary artery bypass grafting were randomly assigned to the aspirin + ticagrelor group or the aspirin + clopidogrel group in a 1:1 ratio. Participants in the aspirin + ticagrelor group took aspirin 100 mg once per day and ticagrelor 90 mg twice per day. Participants in the aspirin + clopidogrel group took aspirin 100 mg once per day and clopidogrel 75 mg once per day. Platelet function was determined before study treatment (0 hours); at 2 hours, 8 hours, 24 hours, and 72 hours after medication; and during follow-up at 30 days after surgery. RESULTS: Inhibition of platelet aggregation at 2 hours after the first drug administration was greater for the aspirin + ticagrelor group than for the aspirin + clopidogrel group (34.2% [interquartile range, 9.1-66.0] vs 5.3% [interquartile range, -14.3-22.0], P < .001) and at all times in the study period (P < .001). More patients reached inhibition of platelet aggregation maximum within 24 hours in the aspirin + ticagrelor group than in the aspirin + clopidogrel group (52.9% vs 27.5%, P = .006). The average inhibition of platelet aggregation maximum from 2 to 24 hours was still greater in the aspirin + ticagrelor group than in the aspirin + clopidogrel group (72.3% ± 15.4% vs 49.2% ± 46.8%, P < .001). There were no differences in terms of bleeding or major adverse cardiac events between the 2 groups. CONCLUSIONS: In patients receiving coronary artery bypass grafting, the onset of action was faster and the peak inhibition of platelet aggregation was higher with ticagrelor than with clopidogrel.
引用
- Xu F, Feng W, Zhou Z, et al. Antiplatelet effects of ticagrelor versus clopidogrel after coronary artery bypass graft surgery: A single-center randomized controlled trial. J Thorac Cardiovasc Surg. 2018. PMID: 30501950. doi:10.1016/j.jtcvs.2018.10.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。